Active	Status	Sponsor type	Region	Phase	Filter
15 Active 1 Inactive 16 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

15 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ligufalimab (AK117) / Akesobio
NCT06601335: A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)	Recruiting	3	510	RoW	AK117 in combination with AK112, Placebo in combination with Pembrolizumab	Akeso	Head and Neck Squamous Cell Carcinoma	01/27	10/27
AK112-206, NCT05382442: A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer	Recruiting	2	254	US, RoW	AK112, AK117, Oxaliplatin, Capecitabine, Irinotecan, Leucovorin, 5-fluorouracil	Akeso, Summit Therapeutics	Metastatic Colorectal Cancer	05/26	08/28
AK117-203, NCT05227664: A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer	Recruiting	2	120	RoW	AK117, AK112, Nab paclitaxel, paclitaxel	Akeso	Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer	07/25	12/26
AK117-205, NCT06196203: A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes	Recruiting	2	90	US, RoW	AK117, Placebo, Azacitidine	Akeso	Higher-risk Myelodysplastic Syndromes	01/26	06/26
NCT06508606: AK117 (Anti-CD47) + Anti-EGFR for R/M HNSCC	Not yet recruiting	2	10	NA	AK117, anti-EGFR	West China Hospital	Head and Neck Squamous Cell Carcinoma	08/26	08/27
AK104-219, NCT05960955: Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma	Recruiting	2	90	RoW	Cadonilimab, AK117, Oxaliplatin, Tegafur-gimeracil-oteracil potassium, Docetaxel, 5-Fluorouracil	Akeso	Resectable Gastric or Gastroesophageal Junction Adenocarcinoma	11/24	11/27
NCT06789848: Ligufalimab and Cadonilimab in Advanced Liver Cancers	Recruiting	2	64	US	Ligufalimab, Cadonilimab	University of Texas Southwestern Medical Center, Akesobio, Josephine Hughes Sterling Foundation	Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Biliary Tract Cancer	05/29	05/30
AK117-202, NCT05214482: A Study of AK112 in Advanced Malignant Tumors	Active, not recruiting	1/2	250	RoW	AK112, AK117, Chemotherapy	Akeso	Advanced Malignant Tumors	05/25	06/26
AK117-201, NCT05229497: A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors	Recruiting	1/2	114	RoW	AK112, AK117, Carboplatin, Cisplatin, 5-Fluorouracil	Akeso	Advanced Malignant Tumors	02/23	02/24
AK117-204, NCT05235542: A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors	Recruiting	1/2	130	RoW	AK104, AK117, Capecitabine tablets, Oxaliplatin, Cisplatin, Paclitaxel, Irinotecan, Docetaxel, 5-FU	Akeso	Advanced Malignant Tumors	03/23	03/24
AK117-103, NCT04900350: A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome	Active, not recruiting	1/2	136	RoW	AK117, Azacitidine	Akeso	Myelodysplastic Syndrome	09/25	12/25
AK117-104, NCT04980885: A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia	Active, not recruiting	1/2	68	RoW	AK117, Azacitidine	Akeso	Acute Myeloid Leukemia	09/25	12/25
AK117-206, NCT06387420: A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia	Not yet recruiting	1/2	180	RoW	AK117, Azacitidine, Venetoclax, Placebo	Akeso	ACUTE MYELOID LEUKEMIA; AML	04/26	04/27
NCT06642792: A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma	Recruiting	1/2	280	RoW	AK129, AK117	Akeso	Classic Hodgkin Lymphoma	11/27	02/28
AK117-102, NCT04728334: A Phase 1 Dose Escalation and Expansion Study of AK117	Completed	1	49	RoW	AK117	Akeso	Neoplasms Malignant	01/22	05/23